公开(公告)号：US08546086B2

公开(公告)日：2013-10-01

申请号：US13035352

申请日：2011-02-25

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： C07K7/06 ,  C07K14/475 ,  C07K16/22 ,  G01N33/53

CPC分类号： C07K14/4756 ,  A61K38/00

摘要： The invention relates, inter alia, to the use of neuregulin-β as an indicator in a method for detecting a neuronal process. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-β and also substances which exert an influence on the status, i.e. the expression and/or post-translational modification, of neuregulin-β, can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.

摘要翻译： 本发明尤其涉及在神经元过程检测方法中使用神经调节蛋白-β作为指示剂。 本发明还涉及使用神经调节蛋白，优选具有等电点在pH 4.3至5.0范围内的神经调节蛋白同种型作为检测和/或发挥对神经元过程的影响的目标，特别是对长时间的影响 - 记忆 因此，神经调节蛋白，特别是神经调节蛋白β以及对神经调节蛋白-β的状态（即表达和/或翻译后修饰）产生影响的物质可用作控制治疗和/或治疗的过程， 减轻神经元疾病，例如 阿尔茨海默氏病。

公开(公告)号：US08377648B2

公开(公告)日：2013-02-19

申请号：US12595678

申请日：2008-04-09

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： G01N33/574

CPC分类号： G01N33/574 ,  G01N2333/4718

摘要： The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and/or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance.

摘要翻译： 本发明涉及一种用于诊断前列腺癌的方法，包括用特异性试剂测定膜联蛋白A3（ANXA3）和/或针对ANXA3的自身抗体。 该方法允许在良性恶变和恶性病症之间进行分化。 此外，该方法具有预后的相关性。

公开(公告)号：US20110294791A1

公开(公告)日：2011-12-01

申请号：US13144349

申请日：2010-01-13

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： A61K31/551 ,  A61P35/00 ,  C07D471/04

CPC分类号： C07D487/04 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/553 ,  A61K31/554 ,  A61K33/24 ,  A61K45/06

摘要： The present invention generally relates to the neuroprotective activity of condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as co-medicaments for the prevention and/or treatment of drug-induced neurotoxic effects in general and neurotoxic side effects during cancer treatments with cytostatic drugs such as platinum-derivatives, e.g. cis-, carbo- and oxaliplatin, taxanes, bleomycin, cyclophosphamide and vincristine etc. Further, these compounds have an intrinsic anti-cancer activity on their own due to PARP-1 inhibition, which prevents NADH depletion in oxidative metabolism of healthy cells thus preventing the shift to anoxygenic, glycolytic metabolism present in many types of tumour cells thus eliminating this crucial metabolic advantage favoring tumour growth. These results exploit the fact of differential PARP-1 expression between many cancer cells and healthy tissues.

摘要翻译： 本发明一般涉及浓缩的二氮杂酮的神经保护活性，例如 缩合苯并二氮杂酮如哌仑西平或代谢为缩合苯并二氮杂酮如奥氮平的化合物。 这些化合物适合作为用于预防和/或治疗药物诱导的神经毒性作用的共同药物，以及用细胞生长抑制药物如铂衍生物（例如，铂衍生物）治疗癌症治疗期间的神经毒副作用。 顺式，卡铂和奥沙利铂，紫杉烷，博来霉素，环磷酰胺和长春新碱等。此外，由于PARP-1抑制，这些化合物本身具有内在的抗癌活性，从而阻止健康细胞的NADH消耗氧化代谢，从而防止 转移到存在于许多类型的肿瘤细胞中的过氧化，糖酵解代谢，从而消除了有利于肿瘤生长的这种关键的代谢优势。 这些结果利用了许多癌细胞和健康组织之间的差异PARP-1表达的事实。

公开(公告)号：US20090286273A1

公开(公告)日：2009-11-19

申请号：US12424962

申请日：2009-04-16

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： C12Q1/02 ,  C07K14/485

CPC分类号： C07K14/4756 ,  A61K38/00

摘要： The invention relates, inter alia, to the use of neuregulin-β as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors.The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-β and also substances which exert an influence on the status, i.e. the expression and/or post-translational modification, of neuregulin-β, can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.

摘要翻译： 本发明特别涉及在活性化合物的筛选方法中使用神经调节蛋白-β作为靶标，特别是对由谷氨酸受体介导的钙浓度变化的影响。 本发明还涉及使用神经调节蛋白，优选具有等电点在pH 4.3至5.0范围内的神经调节蛋白同种型作为检测和/或发挥对神经元过程的影响的目标，特别是对长时间的影响 - 记忆 因此，神经调节蛋白，特别是神经调节蛋白β以及对神经调节蛋白-β的状态（即表达和/或翻译后修饰）产生影响的物质可用作控制治疗和/或治疗的过程， 减轻神经元疾病，例如 阿尔茨海默氏病。

公开(公告)号：US20110263574A1

公开(公告)日：2011-10-27

申请号：US13144342

申请日：2010-01-13

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： A61K31/5513 ,  C07D471/04 ,  A61P27/16

CPC分类号： C07D471/04 ,  A61K31/5513 ,  A61K33/24 ,  A61K2300/00

摘要： The present invention generally relates to the otoprotective activity of condensed diazepinones, e.g. condensed benzodiazepines such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as medicaments for the prevention and/or treatment of otic diseases, e.g. diseases associated with loss of hearing.

摘要翻译： 本发明一般涉及浓缩二氮杂酮的保护活性，例如 缩合苯并二氮杂类如哌仑西平或被代谢为缩合苯并二氮杂酮如奥氮平的化合物。 这些化合物适合作为预防和/或治疗耳科疾病的药物，例如， 与听力丧失相关的疾病

公开(公告)号：US07919582B2

公开(公告)日：2011-04-05

申请号：US12424962

申请日：2009-04-16

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： C07K7/00 ,  C07K14/52 ,  A61K38/08 ,  A61K38/22

CPC分类号： C07K14/4756 ,  A61K38/00

摘要： The invention relates, inter alia, to the use of neuregulin-β as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-.beta. and also substances which exert an influence on the status, i.e. the expression and/or post -translational modification, of neuregulin-.beta., can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.

摘要翻译： 本发明特别涉及使用神经调节蛋白 - 作为活性化合物的筛选方法的目标，特别是对由谷氨酸受体介导的钙浓度变化的影响。 本发明还涉及使用神经调节蛋白，优选具有等电点在pH 4.3至5.0范围内的神经调节蛋白同种型作为检测和/或发挥对神经元过程的影响的目标，特别是对长时间的影响 - 记忆 神经调节蛋白，特别是神经调节蛋白。 因此，也可以使用对神经调节蛋白-ββ的状态（即表达和/或翻译后修饰）产生影响的物质作为用于控制神经元疾病进程，治疗和/或缓解神经元疾病的药剂。 阿尔茨海默氏病。

公开(公告)号：US20070207998A1

公开(公告)日：2007-09-06

申请号：US11632648

申请日：2005-07-18

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： A61K31/554 ,  A61K31/553 ,  A61K31/551 ,  A61K31/55

CPC分类号： A61K31/554 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/553

摘要： x The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, systemic sclerosis, pneumoconiosis or lung cancer. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

摘要翻译： 本发明一般涉及混合的毒蕈碱抑制/ PARP调节的细胞保护活性，特别涉及使用M1毒蕈碱受体和聚（ADP-核糖）聚合酶（PARP）的双重抑制剂作为上皮保护药物，特别是作为药物 预防和/或治疗与重要炎症成分相关的常见肺部疾病中的至少一种，例如严重败血症，急性肺损伤，急性呼吸窘迫综合征，囊性纤维化，哮喘，过敏性鼻炎，慢性阻塞性肺病，肺纤维化， 系统性硬化症，肺尘埃沉着病或肺癌。 特别优选的化合物是缩合的二氮杂酮，例如 缩合苯并二氮杂酮如哌仑西平或代谢为缩合苯并二氮杂酮如奥氮平的化合物。

公开(公告)号：US20100267051A1

公开(公告)日：2010-10-21

申请号：US12770472

申请日：2010-04-29

申请人： Michael Cahill ,  Andre Schrattenholz

发明人： Michael Cahill ,  Andre Schrattenholz

IPC分类号： G01N33/53 ,  C12Q1/06

CPC分类号： G01N33/57434 ,  G01N33/57446 ,  G01N2333/4718

摘要： A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.

摘要翻译： 一种治疗泌尿生殖和/或肠道癌症的方法，包括向哺乳动物施用治疗有效量的至少一种附着蛋白，即A3的膜联蛋白。

公开(公告)号：US20070298448A1

公开(公告)日：2007-12-27

申请号：US10555951

申请日：2004-04-27

申请人： Vukic Soskic ,  Andre Schrattenholz

发明人： Vukic Soskic ,  Andre Schrattenholz

IPC分类号： C12Q1/37 ,  C07H21/04

CPC分类号： C12N9/6408 ,  C12P21/06 ,  G01N33/573 ,  G01N2500/00

摘要： The invention relates to a method for the enrichment, isolation and/or identification of cleavage products of at least one enzyme from a sample. According to the invention, an enzymatically inactive mutant of a protease is used as an affinity material, said mutant furthermore maintaining its specific substrate nature. At least one cleavage product of the protease of which the mutant is used, and at least one cleavage product of the enzyme of which the cleavage products are to be analyzed, comprise at least one structural similarity.

摘要翻译： 本发明涉及从样品中富集，分离和/或鉴定至少一种酶的切割产物的方法。 根据本发明，蛋白酶的无酶突变体用作亲和材料，所述突变体还保持其特异性底物性质。 使用突变体的蛋白酶的至少一种切割产物和其中待分析切割产物的酶的至少一种切割产物包含至少一种结构相似性。

公开(公告)号：US20070265251A1

公开(公告)日：2007-11-15

申请号：US11632649

申请日：2005-07-18

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： A61K31/551 ,  A61P25/00

CPC分类号： A61K31/554 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/553

摘要： The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

摘要翻译： 本发明一般涉及混合的毒蕈碱抑制/ PARP调节的细胞保护活性，特别涉及使用M1毒蕈碱受体和聚（ADP-核糖）聚合酶（PARP）的双重抑制剂作为神经保护药物，特别是作为药物 预防和/或治疗神经系统疾病。 特别优选的化合物是缩合的二氮杂酮，例如 缩合苯并二氮杂酮如哌仑西平或代谢为缩合苯并二氮杂酮如奥氮平的化合物。